Description
Semaglutide is a long-acting GLP-1 receptor agonist. Treatment of obese mice led to reduced body weight, improved oxidative stress indexes, and improved performance in water maze testing. Pretreatment of albino mice with induced ischemia and reperfusion injury with semaglutide showed modulated inflammatory response and oxidative pathway. Rats treated with semaglutide showed inhibited I/R injury-induced cardiomyocyte apoptosis also.